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Abstract 
Due to the pivotal role played by human serum albumin (HSA) in the transport and cytotoxicity of 
titanocene complexes, a docking study has been performed on a selected set of titanocene complexes 
to help clarify the potential mode of action of these titanocenes upon binding HSA. Analysis of the 
docking results has revealed potential binding modes for these titanocenes at the known drug binding 5 
sites in HSA. Additionally, a new alternative binding site for these titanocenes has been postulated.  
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Introduction 
Metal-based antitumour agents have gained significant interest since the discovery of the antitumour 
activities of cis-platin (Fig. 1a).
1 
However, due to toxic side effects of this chemotherapeutic agent
2,3 
such as myelotoxicity and nephrotoxicity, in addition to the high risk of developing tumour resistances, 
research has progressed to other metal-based chemotherapeutic agents such as metallocene dihalides; 5 
Cp2MX2.
4 
Metallocene dihalides, containing a variety of transition metals (M= Ti, V, Nb, Mo), showed 
remarkable antitumour activity when tested in-vivo using simple animal models.
4
 Among all the 
metallocenes tested, titanocene dichloride Cp2TiCl2 (Fig. 1b) was initially found to exhibit the most 
impressive chemotherapeutic activity against colon, lung and breast cancers.
3
 Titanocene dichloride 
entered clinical trials in 1993, but results from phase II clinical trials in patients with advanced renal 10 
cell carcinoma and breast metastatic carcinoma were not sufficiently promising
5,6 
and further clinical 
trials were abandoned. In general, albumin is important to cancer cells as a nutrient and energy supply 
in order to facilitate their rapid growth. An anti-cancer drug bound to albumin is of significant 
advantage as this facilitates the uptake across the endothelial cell wall of blood vessels of tumours in 
an albumin receptor-mediated transport pathway.
7
 15 
 
In the last two decades, there has been a growing interest towards the development of new substituted 
titanocene dichloride derivatives (Fig. 2). McGowan and co-workers synthesized a number of ionic 
titanocenes which have improved water solubility and were found to be highly effective against 
ovarian cancers.
8-10 
Another series of water soluble titanocene dichloride complexes was synthesized 20 
by Baird et al. and found to be effective against lung and ovarian cancers.
11
 On the other hand, the 
current efforts by Tacke et al. have focused on the development of substituted titanocene complexes 
starting from substituted fulvenes. This has resulted in the synthesis of substituted titanocenes that 
exhibit remarkable antitumour activity against kidney carcinoma LLC-PK cell line, with IC50 values 
reaching 5.4 µM range.
12-35
 Synthetic efforts are ongoing and aimed at developing new titanocene 25 
complexes exhibiting potent cytotoxic activity along with reduced side effects and non-cross 
resistance.  
 
While the exact mechanism of action of titanocene dichloride complexes is still poorly understood, 
several investigations have shown that both transferrin and albumin could serve as possible routes for 30 
the delivery of titanocenes to cancer cells
36-39 
,whereas DNA is believed to be the main cellular target 
for these titanocene complexes.
40-42 
Tacke and co-workers have confirmed the crucial role played by 
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binding to serum albumins in the cytotoxicity of titanocene complexes, since cancer cells are known to 
be leaky for albumin due to enhanced vascular permeability and retention effects.
7 
Research has shown 
for example that Titanocene Y has only a cytotoxic effect in the presence of serum albumin when 
tested on the oestrogen-depending breast cancer cell line MCF-7.
7
 Furthermore, evidence for the 
binding mode of Titanocene Y was presented from a simple molecular docking experiment. Using the 5 
crystal structure of an albumin-fatty acid complex, a similarly sized fatty acid molecule was removed 
in order to create a hypothetical binding pocket for Titanocene Y. Results showed that a 
complementary-shaped binding site was apparent and the titanocene could be stabilized by hydrogen 
bonds involving the p-methoxy group of the sandwich complex and the CH2OH group of a serine (Ser) 
residue from the protein.
7
 10 
 
Crystallographic determination of the 3-D structure of human serum albumin (HSA) has shown that 
HSA comprises three homologous α-helical domains named I, II and III with each domain subdivided 
into two sub-domains A and B.
43,44 
A crystallographic study by Curry et al. has identified a total of 7 
binding sites that are occupied by medium and long chain fatty acids, with additional sites for medium 15 
chain fatty acids yielding a total of 11 possible binding sites (Fig. 3).
45
 Extensive studies on drug-
binding sites in HSA has resulted in the accepted proposal of two principal primary drug-binding sites, 
named drug-site I and II located in the sub-domains IIA and IIIA, respectively (Fig. 3).
46
 
 
Molecular docking studies are an important tool in providing crucial understanding of the possible 20 
binding mode of drugs and as a result they can be used to identify potential lead compounds. Examples 
include a Surflex-Dock study by Lee et al., which was carried out in order to elucidate possible 
binding modes of certain cytotoxic compounds (benz[b]oxepines and 12-
oxobenzo[c]phenanthridinones) as topoisomerase inhibitors.
47
 In addition, Montembault et al. reported 
the synthesis of antiviral drugs as potential Tat HIV-1 inhibitors, called TDS compounds.
48
 These TDS 25 
molecules were designed with support from docking experiments.
48 
As a general principle, molecular 
docking studies typically screen datasets of small molecules by orienting and scoring the molecules 
when bound to the active site of a protein. Top ranked molecules may become lead compounds for 
drug development and optimization. Indeed, docking studies play an important role in rational drug 
design and discovery. 30 
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To date, no systematic molecular docking studies have been reported for the potential drug class 
titanocenes. This paper reports, for the first time, a systematic receptor-based docking approach for a 
database of 16 titanocene derivatives exhibiting a range of structural and biological activity in order to 
shed light on understanding the mode of action of these titanium-based anticancer drugs against HSA. 
 5 
 
Materials and Methods 
The described study compromised 16 titanocene derivatives taken from the literature 
12
 (see Table 1), 
which constituted the dataset. The compounds were selected based on the following criteria:  
1. All selected compounds are tested for their cytotoxic activity on the same cancer cell line in 10 
order to enable a direct comparison of their efficacy.  
2. The selected compounds are diverse in both structure and antitumour activity, expressed as 
IC50, allowing structural features to be correlated to cytotoxic activity.  
3. Only achiral compounds were selected for this study in order to avoid complication connected 
to the presence of stereoisomers. Up to now it has not been possible to separate the 15 
stereoisomers of chiral substituted-titanocenes and as a result it is not possible to assign IC50 
values to individual stereoisomers. Such mixtures complicate the structure-activity relationship. 
 
Furthermore, the titanocenes chosen were representative of different classes of substituted titanocene 
dichlorides, namely benzyl-substituted titanocenes 1a-d and 2a-c, achiral: bis-dimethylamino-20 
functionalized titanocenes 3a-c, diheteroaryl-substituted titanocenes 4a-c and diaryl-substituted 
titanocenes 5a-c. Moreover, these titanocenes showed a wide range of cytotoxic activity and all were 
tested against the same (LLC-PK) cell line using an MTT-based assay, as described in the literature
12
. 
 
The three-dimensional structure of each titanocene derivative forming the dataset was built using the 25 
Sketcher module in the molecular modeling software SYBYL.
49
 The basic unit Cp2TiCl2 present in all 
titanocenes was modelled using the force field parameters reported by Doman et al.
50 
after converting 
them to the SYBYL format. Subsequent energy minimization was performed using the standard Tripos 
force field with a distance dependent dielectric constant and the Powell method with 0.05 kcal/mol 
energy gradient convergence criteria. The bond lengths and angles for the Cp2TiCl2 basic unit, 30 
obtained following minimization, were comparable to the reported values of the crystal structures of 
substituted titanocene compounds.
26,33
 Repeated minimization was performed with 1000 iterations, and 
 6  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
each structure was obtained in its lowest energy conformer, which was used in the subsequent docking 
experiments in each case. 
 
The crystal structures of HSA complexed with decanoic acid (capric acid) (PDBid 1E7E), diazepam 
(PDBid 2BXF), ibuprofen (PDBid 2BXG) and warfarin (PDBid 2BXD) were obtained from the 5 
Protein Data Bank (PDB).
51 
In order to prepare HSA for the docking experiments duplicated chains, 
wherever present, as well as water molecules were removed. Additionally, all ligands such as capric 
acid, diazepam, ibuprofen and warfarin were extracted from the coordinate files of HSA complexed 
with capric acid (1E7E), diazepam (2BXF), ibuprofen (2BXG) and warfarin (2BXD), respectively. 
Finally, the protein structures were prepared for the docking runs using the Biopolymer Structure 10 
Preparation Tool implemented in the programme SYBYL. Docking experiments utilized the Surflex- 
Dock automatic docking algorithm.
52 
This compromises an empirical scoring function and a search 
engine to dock ligands into the protein ligand binding sites using a protomol-based method.
52
 Three 
different types of probes; hydrophobic, H-bond donor and H-bond acceptor were placed into each 
protein binding site in multiple positions and a scoring function then oriented the probes in order to 15 
optimize the interactions with the protein. High scoring probes represent “sticky spots”, which are 
merged into a pocket. This pocket is called the protomol, which is a computational representation of 
the assumed ligands that interact within that binding site. 
 
The program PyMOL
53
 was used for visualization of the docking results. In order to calculate the 20 
hydrogen bond (H-bond), van der Waals (vdW) and hydrophobic interactions generated by the docking 
process, the resulting PDB files from the docking runs were input to the program CONTACT, 
available in the CCP4 programme suite.
54
 Potential H-bonds were assigned if the distance between two 
electronegative atoms was less than 3.3 Å, whereas any separation greater than 3.3 Å, but less than 4.0 
Å, was considered a vdW interaction. 25 
 
Results and discussion 
Validation of docking method 
The ligands; diazepam, ibuprofen (at two binding sites referred to ibuprofen 1 and ibuprofen 2) and 
warfarin were first extracted from the corresponding coordinate files; 2BXF, 2BXG and 2BXD, then 30 
docked again into each of the corresponding extracted files following the structure preparation 
procedures implemented in SYBYL program. This experiment revealed that each of these docked 
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ligands was found to exactly dock into its corresponding ligand binding site in the protein structure. 
This provides a positive validation of the docking method used in the study. 
 
Docking studies  
Two different types of docking runs were performed whereby; i) the ligand is centered and docked at a 5 
specified binding site and ii) the ligand is docked automatically in a binding site defined by the 
program. 
 
Using the docking based approach on a pre-aligned ligand binding site, each of the modelled and 
minimized titanocene derivatives were docked sequentially into all four different ligand binding sites; 10 
warfarin, diazepam and the two ibuprofen sites used in the study. This is in addition to an automated 
docking process into the prepared HSA of (1E7E) which was not based on any ligand binding site, and 
a further docking process based on the fatty acid (capric acid) binding sites FA1, 2 and 5 of 1E7E (as 
defined by Curry et al.).
45 
 15 
Table 2 summarizes the potential polar contacts and vdW interactions formed between the titanocenes 
under study and each of the potential ligand binding site residues in HSA as obtained following 
docking of each of the titanocenes into 2BXD (HSA complexed with warfarin), 2BXF (HSA 
complexed with diazepam) and 2BXG (HSA complexed with ibuprofen). Graphical representative 
examples of the docking results are presented in Fig.4. 20 
 
Docking at the warfarin binding site of (2BXD) 
Benzyl titanocenes, compounds 1a, 1b and 1c docked into the warfarin binding site of 2BXD were 
each found to make one H-bond interaction between the Ti center and the nitrogen center NZ of 
Lys199. Titanocene 1d was seen to form potential H-bonds by its chlorines with Glu292 and Lys199 25 
of the HSA when docked into the warfarin binding site. 
 
Docking of benzyl-substituted titanocenes 2a and 2b into the warfarin binding site of 2BXD revealed 
that potential H-bonds were formed between their chlorines and Gln196 and Lys199. 2a was found to 
show an additional H-bond between the oxygen center O(1) and OE2 atom of Glu292, while docking 30 
of 2c showed two H-bonds, one formed between the Ti center and the nitrogen center NZ of Lys199 
and the other between Cl(2) and the backbone oxygen atom of Ala291. 
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Bis-amino-functionalized titanocenes, compounds 3a, 3b and 3c docked into the warfarin binding site 
of 2BXD showed that titanocene 3a formed only one H-bond, between its chlorine center Cl(1) and the 
nitrogen atom NE2 of His242. In comparison titanocene 3b formed three H-bonds, one between Cl(1) 
and His242 and the other two between N(4), S(2) and Lys199. On the other hand, titanocene 3c was 5 
shown to form four H-bonds, two between Cl(1) and Arg222/Ala291, one between the other chlorine 
center and Lys199 and one between N(3) and Glu292.  
 
Docking of achiral diheteroaryl-substituted titanocene 4a into the warfarin binding site of 2BXD was 
found to form two H-bonds, by Cl(1) and O(4) with Arg222 and Lys199 respectively. In contrast, 10 
titanocene 4b showed three potential H-bonds, two between Cl(2) and Arg222/Ala291 and one 
between S(4) with Glu292. Compound 4c exhibited two H-bonds between Cl(2) to both Arg222 and 
Ala291. 
 
Docking of achiral diaryl-substituted titanocene 5a showed a network of eight potential H-bonds, 15 
formed by Cl(1), O(1), O(5) and O(6) atoms to Lys199, Arg222, Lys195 and Glu292, respectively, and 
four H-bonds were shown between O(3) and Arg257, His288 and Ser287. Compound 5b appeared 
capable of making three H-bonds, two by its chlorine atoms to Lys199 and one between N(4) atom to 
Glu292. And compound 5c showed the formation of two H-bonds, between its Ti, O1 atoms and 
Arg222/Arg257, respectively. 20 
 
Docking at the diazepam binding site of (2BXF) 
Docking of 1a into the diazepam binding site of 2BXF was found to form two H-bonds between the 
chlorine center Cl(2) and both the oxygen atom OG of Ser489 and the OH group of Tyr411. Whereas 
1b and 1c were each shown to form three H-bonds by their chlorines to OG atom of Ser489 and OH 25 
group of Tyr411. In addition, 1b was shown to form two further H-bonds between the oxygen center 
O(2) and side chain atoms ND2 and the backbone nitrogen of Asn391, whereas 1c was shown to form 
another H-bond between the oxygen center O(4) and SG atom of Cys392. Docking of 1d resulted in 
two H-bonds that were formed from its chlorines with Asn391 and Arg410. 
 30 
On the other hand, docking of 2a, 2b and 2c into the diazepam binding site gave different interactions. 
Compound 2a was found to form a single H-bond between the chlorine center Cl(2) and OG atom of 
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Ser489. Compound 2b was also found to form a single H-bond between Cl(1) and OH group of 
Tyr411, whereas compound 2c showed four H-bond interactions, two formed through Cl(2) with both 
OG atom of Ser489 and OH group of Tyr411, and two formed between its N(1) with side chain atoms 
NE and NH2 of Arg410. 
 5 
Docking 3a into the diazepam binding site formed three H-bonds, two between the chlorine center 
Cl(2) to both Ser489 and Tyr411, and the other one with N(6) atom to Asn391. Docking 3b showed 
only two H-bonds through the chlorine Cl(1) and the nitrogen N(6) centers with the side chain atoms 
ND2 and OD1 of Asn391, respectively. Compound 3c appears able to form four H-bonds, two with the 
chlorine centers  Cl(1) and Cl(2) to ND2 atom of Asn391 and OH group of Tyr411, respectively, and 10 
two by the nitrogen centers N(1) and N(6) to the side chain atoms NE of Arg410 and OD1 of Asn391, 
respectively.  
 
Compound 4a docked into the diazepam binding site of 2BXF was shown to form four H-bonds, two 
between its chlorines with Asn391 and Tyr411 and two through the oxygen centers O(1) and O(3) to 15 
Asn391. Compound 4b showed two H-bonds through its chlorines to Asn391 and Tyr411. And 
compound 4c was shown to form three potential H-bonds by its chlorines with Asn391.  
 
Compound 5a docked into the diazepam binding site of 2BXF was shown to form seven H-bonds, two 
between the chlorine centers Cl(1), Cl(2) with Arg485 and Asn391, respectively, and the other five 20 
through the oxygen centers O(3), O(5), O(6), O(7) and O(8) with Ser489, Cys392, Gly434, Tyr411 and 
Asn391, respectively. 5b was shown to form five H-bonds, one by Cl(1) with Tyr411, three by the 
nitrogen center N(2) with Arg485 and Glu450, and one by the nitrogen center N(3) with Gln390. 5c 
was found to form five H-bonds, three through its chlorines with both Ser489 and Tyr411, and two by 
the oxygen centers O(3) and O(4) with Gly434 and Glu450, respectively.  25 
 
Docking at the ibuprofen binding site of (2BXG) 
No polar contacts were found with any of the amino acid residues upon docking of titancenes 1a and 
1d into the ibuprofen binding site of 2BXG, whereas docking of 1b and 1c showed H-bonds between 
their chlorines with both Arg410 and Asn391.  30 
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Docking of 2a, 2b and 2c into the ibuprofen binding site were found to form potential H-bonds 
between their chlorines and Asn391 and Arg410. Additional H-bonds were shown through O(1) center 
of 2a to Lys414 and through N(2) center of 2c to both Lys414 and Ser489.  
 
Compound 3a docked into the ibuprofen binding site of 2BXG was shown capable of forming a total 5 
of six H-bonds, two between its chlorines to Ser489 and Asn391, two between the oxygen center O(4) 
to Asn391, and two through O(1), N(5) atoms to Arg410 and Ser489, respectively. Compound 3b was 
found to form five H-bonds, three by its chlorines to Lys414 and Ser489 and two by S(4) with Asn391. 
And compound 3c exhibited a network of five potential H-bonds through its chlorines with Arg410 
and Asn391.  10 
 
Compound 4a was found to form a network of five potential H-bonds, four through its chlorines with 
Arg410 and Asn391 and one by O(4) center with Arg410. Compound 4b showed a total of five H-
bonds between its chlorines with Arg410 and Asn391. And compound 4c was found to form four H-
bonds, two through its chlorines with Asn391 and another two by the nitrogen centers N(2) and N(4) 15 
with Asn391 and Arg410, respectively.  
 
Docking of compound 5a appeared capable of making a network of eight potential H-bonds, three 
between chlorine center Cl(2) with NH1, NH2 atoms of Arg410 and OD1 atom of Asn391, one 
between Ti center with Arg410, and four through the oxygen centers; O(6) with Leu430 and O(8) with 20 
Ser489 and Arg485. Compound 5b showed two H-bonds through Cl(1) with Arg410. And compound 
5c was shown to form four H-bonds, three between its chlorines with Lys414 and Ser489, and one 
through O(4) center with Tyr411.  
 
The automated docking site 25 
Table 3 lists the polar contacts together with the vdW interactions between titanocenes under study and 
HSA (1E7E) as found by automated docking run. 
The automated docking process was run without taking into account a specific ligand binding site. All 
titanocenes under investigation were shown to form several potential H-bonds and vdW interactions 
with different amino acid residues from both binding sites; drug site I and drug site II. Actually 30 
interactions were shown with the following amino acid residues: Lys195, Leu198, Lys199, Phe211, 
Trp214, Arg218, Val344, Glu450, Asp451, Leu453, Ser454, Leu481 and Arg485.  
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Automated docking revealed that these titanocenes can bind at a different site than previously 
identified for HSA. In fact, instead of binding to either known drug binding sites I and II, these 
compounds appear to span a large region making several potential H-bonds and vdW interactions with 
amino acid residues from both known drug binding sites, drug site I and II on HSA. This is not 
surprising when the actual size of these compounds is taken into account. 5 
 
Overall comparison of potential binding sites 
Proteins in general, contain pockets (or cavities) where small ligands (peptides, nucleic acids, sugars, 
organic molecules, metals, etc) can bind. Furthermore, it is well known that proteins are flexible 
molecules that can accommodate ligands with vastly different sizes and shapes. Importantly, there are 10 
several factors that have a significant impact on the strength and specificity of ligand binding, such as 
lipophilicity, H-bonding potential and complementarity in shape. Minor structural modifications can 
have unpredictable effects on drug binding. 
 
Generally speaking, higher cytotoxic activity IC50 range (21-120) µM was observed for benzyl-15 
substituted titanocenes 1a-d compared to the heteroaryl-substituted titanocenes 2a-c with IC50 range 
(91-160) µM. This could be due to a higher number of vdW interactions that were made by titanocenes 
1a-d at drug site I compared to that of 2a-c. 
Benzyl-sustituted  titanocene with p-methoxy group, compound 1b showed an impressive 10-fold 
increase in cytotoxicity compared to its NMe2 substituted analogue 1a. This possibly could be due to 20 
the larger number of vdW interactions that titanocene 1b is forming compared to 1a. 
A comparison of the docking results for compounds 2a-c, 3a-c and 4a-c with their cytotoxic activity 
revealed a general observation. As a general trend, compounds bearing N-methylpyrrol substitution on 
the cyclopentadienyl rings were shown to have higher cytotoxic activity than those where the 
substitution is a thienyl or furyl group. Investigating the types of interactions, it was observed that 25 
compounds with N-methylpyrrol substitution made H-bonds through their methylamino groups with 
thr nitrogen atoms of the side chain Arg410, suggesting the importance of this type of interaction with 
HSA on the cytotoxic activity of these compounds. 
Comparison of mono- and di-heteroaryl substituted titanocenes with the N-methyl pyrrol substitution, 
2c and 4c showed that compound 4c exhibited higher number of vdW interactions at drug sites I and II 30 
than did compound 2c which could explain the differences in their cytotoxic activity. 
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Furthermore, although compound 4c makes fewer H-bonds compared to 4a or 4b, it has higher 
cytotoxic activity than either 4a or 4b. This may suggest that vdW interactions play an important role 
in its binding mode to HSA, hence the outcome on cytotoxic activity (since 4c makes a larger number 
of vdW interactions with residues in the warfarin binding site). 
On the other hand, diaryl-substituted titanocene 5b have higher cytotoxic activity when compared to 5 
the monoaryl-substituted titanocene 1a. This is probably because of large number of H-bonds that 
titanocene 5b formed with the amino acid residues of both drug site I and drug site II of HSA. 
These differences highlighted the importance of molecular descriptors, such as H-bonding potential, 
lipophilicity and shape complemantarity in determining the binding mode to HSA. 
 10 
The docking results to date indicate that these titanocenes can make several interactions through H-
bonding and vdW interactions with amino acid residues of the warfarin binding site of 2BXD (known 
as drug site I), as well as with those of diazepam and ibuprofen binding sites of 2BXF and 2BXG 
(known as drug site II).Thus, it is plausible that these titanocenes can bind HSA at either primary 
binding sites I and II located in subdomains IIA and IIIA, respectively. Otherwise, these titanocenes, 15 
like ibuprofen, may bind at multiple sites on HSA. Certainly, the numerous H-bonds shown by 
compounds suggest that these titanocenes show high specificity towards drug site I, and/or drug site II. 
Docking results for drug site II based on diazepam and ibuprofen binding sites, suggested that these 
titanocenes may bind in slightly two different positions within the binding site itself, however this 
cannot be substantiated without experimental evidence.  More specifically, docking results showed that 20 
these titanocenes were found to make interactions with the amino acid residues of HSA at different 
fatty acid (FA) sites, but no interactions were noticed with the amino acid residues at FA1, 2 and 5 
sites. Therefore, in order to gain insight at the whole picture of the binding mode of these titanocenes 
at different possible binding sites, further docking processes based on FA1, FA2 and FA5 sites were 
run. Interestingly, docking of these titanocenes into fatty acid sites 1 (FA1), 2 (FA2) and 5 (FA5) of 25 
1E7E revealed that the ligands were more exposed to the solvent (Fig. 5) which may be indicative of 
weaker and less specific binding at these sites on HSA. Furthermore, automated docking revealed an 
alternative binding pocket for these titanocenes to bind, which again requires experimental data to 
substantiate. 
 30 
Conclusions 
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Our results indicate potential binding through H-bonding and van der Waals (vdW) interactions of 
these titanocenes to human serum albumin at the known drug binding sites. Additionally, we 
hypothesize a new alternative binding site for these titanocenes that spans two of the known drug 
binding sites. Based on the comprehensive docking studies performed herein, these titanocene 
derivatives may bind to either of the HSA primary drug binding sites I or II, or, alternatively these 5 
molecules may bind to multiple sites, as observed with other drugs such as ibuprofen. 
 
This work provides new insight into the specificity and shape complementarity of binding of these 
titanocenes to each known drug binding pocket in HSA and reveals a potentially new binding pocket 
for these derivatives. Site-directed mutagenesis studies, as well as X-ray crystallographic analysis of 10 
ligand-protein complexes can provide validation of the most likely ligand binding site(s) for the 
titanocene derivatives. This work is currently underway. 
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Table 1 
Structure
a
 Compound  R,X IC50,μM 
(LLC-PK)
b 
 
 
1a 
1b 
1c 
1d 
 
NMe2 
OMe 
OCH2CH2OMe 
morpholine 
 
120 
21 
43 
25 
 
 
2a 
2b 
2c 
 
O 
S 
NMe 
 
160 
150 
91 
 
 
3a 
3b 
3c 
 
O 
S 
NMe 
 
240 
270 
36 
 
 
4a 
4b 
4c 
 
O 
S 
NMe 
 
140 
240 
32 
 
 
5a 
 
OMe 
 
74 
 
 
5b 
5c 
 
NMe2 
OMe 
 
40 
38 
 
a 
Select atoms are numbered for ease of identification in the results section 
b
LLC-PK Kidney carcinoma cell line 
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Table 2. 
  
Compound H-bonds with Distances (Å)
a
 
 
Number of vdW 
interactions 
Drug-site I
b 
Drug-site II
c 
Drug-site II
d 
Drug-site I
b 
Drug-site II
c,d 
1a Ti…NZ Lys199                  3.07
 Cl2…OG Ser489                2.98 
Cl2…OH Tyr 411               2.77 
___ 72 62            49 
1b Ti…NZ Lys199                  3.02 Cl1…OG Ser489                3.01
 
Cl2…OG Ser489                2.91 
Cl2…OH Tyr411                2.71 
O2…ND2 Asn391              3.21 
O2…N Asn391                   2.91 
Cl1…ND2 Asn391             3.03 
Cl1…OD1 Asn391             2.81 
Cl2…NE Arg410                2.96 
Cl2…NH2 Arg410             2.50 
 
79 67            63 
1c Ti…NZ Lys199                  3.16 Cl1…OG Ser489                3.17 
Cl1…OH Tyr411                2.83 
Cl2…OG Ser489                3.05 
O4…SG Cys392                 3.03 
Cl1…NE Arg410                3.07 
Cl1…NH2 Arg410             2.67 
Cl2…ND2 Asn391             3.18 
Cl2…OD1 Asn391             2.97 
O1…N Gly434                   3.17 
74 65            84 
1d Cl1…OE2 Glu292              2.79 
Cl2…NZ Lys199               2.26 
Cl1…OD1 Asn391            3.18 
Cl2…NE Arg410                3.14 
___ 87 72            40 
2a Cl2…OE1 Gln196              3.29 
Cl2…NZ Lys199                2.73 
O1...OE2 Glu292                2.97 
Cl2…OG Ser489                3.01 Cl1…ND2 Asn391             2.83 
Cl1…OD1 Asn391             2.75 
Cl2…NH2 Arg410             2.57 
O1…NZ Lys414                 2.82 
50 67            56 
2b Cl1…OE1 Gln196              3.10 
Cl1…NZ Lys199                3.21 
Cl1…OH Tyr411                2.61 Cl1…ND2 Asn391             2.94 
Cl1…OD1 Asn391             2.75 
Cl2…NE Arg410                3.08 
Cl2…NH2 Arg410             2.60 
50 68            58 
2c Ti…NZ Lys199                  3.00 
Cl2…O Ala291                   3.22 
Cl2…OG Ser489                2.78 
Cl2…OH Tyr411                2.86 
N1…NE Arg410                 3.00 
N1…NH2 Arg410              3.07 
Cl1…NH2 Arg410             2.76 
Cl2…NH2 Arg410             2.95 
Cl2…OD1 Asn391             2.10 
N2…NZ Lys414                 3.12 
N2…O Ser489                    3.29 
45 56             79 
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Table 2 (con’t)                          
                                                       
                                                                                                                                                                                                              
Compound H-bonds with Distances (Å)
a
 
 
Number of vdW 
interactions 
Drug-site I
b 
Drug-site II
c 
Drug-site II
d 
Drug-site I
b 
Drug-site II
c,d 
3a Cl1…NE2 His242               3.29 Cl2…OG Ser489                 3.16 
Cl2…OH Tyr411                3.22 
N6…OD1 Asn391              2.92 
Cl1…OG Ser489                 2.55 
Cl2…ND2 Asn391             3.07 
O1…NH1 Arg410               3.03 
O4…ND2 Asn391              2.65 
O4…OD1 Asn391              3.04 
N5…OG Ser489                 3.16 
90 59             48 
3b Cl1…NE2 His242               3.23 
N4…NZ Lys199                 3.04 
S2…NZ Lys199                  2.55 
Cl1…ND2 Asn391             2.23 
N6…OD1 Asn391             2.93 
 
Cl1…NZ Lys414                3.23 
Cl1…O Ser489                   2.97 
Cl2…OG Ser489                2.18 
S4…ND2 Asn391               2.12 
S4…OD1 Asn391               2.78 
75 60             53 
3c Cl1…NH1 Arg222            2.99 
Cl1…O Ala291                 2.67 
Cl2…NZ Lys199                2.98 
N3…OE2 Glu292              3.27 
Cl1…ND2 Asn391             2.35 
Cl2…OH Tyr411                3.10 
N1…NE Arg410               3.09 
N6…OD1 Asn391             2.92 
 
Cl1…NE Arg410                2.42 
Cl1…NH2 Arg410           2.93 
Cl2…NH2 Arg410           2.69 
Cl2…ND2 Asn391             3.27 
Cl2…OD1 Asn391             2.57 
81 79             60 
4a Cl1…NH1 Arg222          3.12 
O4…NZ Lys199             2.66 
Cl1…ND2 Asn391             2.82 
Cl2…OH Tyr411                3.10 
O1…ND2 Asn391            3.10 
O3…OD1 Asn391            3.02 
 
Cl1…NE Arg410                2.90 
Cl1…NH2 Arg410             2.92 
Cl2…NH2 Arg410           2.34 
Cl2…OD1 Asn391             2.20 
O4…NE Arg410                2.98 
70 77             83 
4b Cl2…NH1 Arg222          2.96 
Cl2…O Ala291               3.06 
S4…OE2 Glu292           2.56 
Cl1…ND2 Asn391             2.79 
Cl2…OH Tyr411                3.16 
Cl1…NE Arg410                2.38 
Cl1…NH2 Arg410             3.25 
Cl2…NH1 Arg410             3.28 
Cl2…NH2 Arg410            2.24 
Cl2…OD1 Asn391             2.65 
88 62             73 
4c Cl2…NH1 Arg222          2.99 
Cl2…O Ala291               2.85 
Cl1…ND2 Asn391             2.29 
Cl1…OD1 Asn391             3.20 
Cl2…OD1 Asn391             2.97 
Cl1…ND2 Asn391             2.87 
Cl1…OD1 Asn391             2.74 
N2…ND2 Asn391              3.30 
N4…NH1 Arg410              3.24 
93 68             73 
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Table 2 (con’t) 
 
 
 5 
Compound H-bonds with Distances (Å)
a
 
 
Number of vdW 
interactions 
Drug-site I
b
 Drug-site II
c
 Drug-site II
d
 Drug-site I
b
 Drug-site II
c,d
 
5a Cl1…NZ Lys199                 2.46 
O1…NH1 Arg222               3.21 
O3…NE Arg257                  3.21 
O3…NH2 Arg257               2.06 
O3…N His288                     2.96 
O3…O Ser287                     2.16 
O5…NZ Lys195                  3.28 
O6…OE1 Glu292                3.26 
Cl1…NH1 Arg485            3.13 
Cl2…OD1 Asn391            2.08 
O3…O Ser489                   2.68 
O5…S Cys392                  3.06 
O6…N Gly434                  2.95 
O7…OH Tyr411               3.03 
O8…OD1 Asn391            2.97 
Cl2…NH1 Arg410              2.94 
Cl2…NH2 Arg410              2.18 
Cl2…OD1 Asn391              2.37 
Ti…NH2 Arg410                 3.14 
O6…O Leu430                    2.86 
O8…OG Ser489                  2.95 
O8…O Arg485                    2.77 
O8…NE Arg485                  3.22 
166 126           126 
5b Cl1…NZ Lys199                 2.53 
Cl2…NZ Lys199                 2.48 
N4…O Glu292                    2.59 
 
Cl1…OH Tyr411              3.16 
N2…NE Arg485               3.09 
N2…NH2 Arg485             3.30 
N2…OE1 Glu450             3.15 
N3…OE1 Gln390             2.66 
Cl1…NE Arg410                 3.26 
Cl1…NH1 Arg410              2.37 
143 113             49 
5c Ti…NH1 Arg222                3.02 
O1…O Arg257                    2.69 
Cl1…OG Ser489               3.09 
Cl1…OH Tyr411              3.15 
Cl2…OG Ser489               3.30 
O3…N Gly434                  3.22 
O4…OE1 Glu450             2.39 
Cl1…NZ Lys414                 2.85 
Cl1…O Ser489                    2.65 
Cl2…N Ser489                    3.22 
O4…OH Tyr411                  3.14 
111 116             88 
 
a
The potential hydrogen bonds were assigned if the distance between
 
two electronegative atoms was <3.3 Å. The van der Waals
 
interactions were assigned where the 
separation between non-bonded hydrogen atoms was <4 Å
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  21 
b
 known binding site for warfarin 
c
 known binding site for diazepam 
d
 known binding site for ibuprofen 
 
         5 
.
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Table 3 
 
 5 
a
The potential hydrogen bonds were assigned if the distance between
 
two electronegative atoms was <3.3 Å. The van der Waals
 
interactions were assigned where the 
separation between non-bonded hydrogen atoms was <4 Å.
Cpd H-bonds with distances (Å)
a
 Number 
of vdW
a
 
Cpd H-bonds with distances (Å) Number 
of vdW 
Cpd H-bonds with distances (Å) Number 
of vdW 
1a Cl1...NE1 W214            2.98     
Cl1...NH1 R218            3.18 
Cl2...O E450                  3.07 
Cl2...OG S454               2.93 
75 
 
1b 
 
O1... OD1 D451           3.18           
O2...NE R485               3.00 
73 1c O1...OD1 D451             2.91     
O2...NZ K199               2.93 
83 
1d Cl1...O E450                  3.06 
Cl1...OG S454               2.89 
Cl2...OD1 D451            2.29 
Cl2...O D451                 2.97 
O1...N R485                  3.07 
80       
2a Cl2...NE1 W214            2.64 
O1...NE1 W214             3.16 
O1...OE2 E450              3.18 
64 2b S2...O L481                   2.63   57 2c Cl1...OG S454               3.16    63 
3a Cl1...NZ K199               2.23 
Cl2...NH1 R218            2.98 
N3...NE1 W214             2.90 
N6...NZ K199                3.04 
O4...NZ K199                3.13 
 
82 3b Cl1...NH1 R218            2.50    
Cl1...NH2 R218            2.87 
N6...NE1 W214             2.93 
90 3c Cl1...NH1 R218            3.20   
Cl1...NH2 R218            2.58 
Cl1...OD1 D451            2.89 
Cl1...OD2 D451            2.92 
Cl2...NE R218               3.01 
Cl2...NH1 R218            3.02 
N1...NZ K199               2.90 
N6...NE1 W214             2.75 
74 
4a Cl1...NE1 W214            2.83 
Cl2...NE1 W214            3.86   
O2...OG S454                2.98 
 
80 4b Cl1...OD1 D451            2.94    
Cl2...O D451                 2.78 
Cl2...OD1 D451            3.27 
Cl2...OG S454               2.50 
84 4c Ti...NE1 W214              3.28 
N4...OG S454                3.04 
99 
5a Cl2...OG S454               2.38 
O5...OD2 D451             2.59    
 
140 5b Cl1...OG S454               2.18     
Cl2...OD1 D451            2.04     
103 5c Cl1...OG S454               2.38 
Cl1...O D451                 2.76    
Cl2...OD1 D451            2.58    
99 
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Table 1 Structures of the titanocenes derivatives (1a-d, 2a-c, 3a-c, 4a-c, 5a-c) in the dataset with their 
corresponding IC5o values. 
 5 
Table 2 Summary of the polar contacts and vdW interactions between the titanocene derivatives (1a-d, 
2a-c, 3a-c. 4a-c, 5a-c) and the known drug binding sites of HSA (2BXD, 2BXF, 2BXG). 
 
Table 3 Summary of the polar contacts and vdW interactions between the titanocene derivatives (1a-d, 
2a-c, 3a-c. 4a-c, 5a-c) and HSA (1E7E) based on automated docking, where a new potential binding 10 
site has been postulated. 
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Fig. 1 Structures of Cis-platin and titanocene dichloride.  
 
Fig. 2 Representative examples of the substituted titanocene dichloride derivatives, a) ionic 
titanocenes, b) benzyl titanocene (Titanocene 
Y) derived from fulvene. 5 
 
Fig. 3 Cartoon diagram of the crystal structure of human serum albumin complexed with capric acid 
(PDBid  1E7E) showing the three domains colour coded and labelled I – III (each with two sub-
domains A and B), the bound fatty acids (FA) in magenta sticks, sties labelled 1-9, and the two drug-
binding sites, drug site I and drug site II, located in the sub-domains IIA and IIIA, respectively. 10 
 
Fig. 4 Docking results for the titanocene derivatives a) 1b at the warfarin binding site of HSA (PDB 
code, 2BXD), b) 1b at the diazepam binding site of HSA (PDB code, 2BXF), c) 3c at the warfarin 
binding site of HSA (PDB code, 2BXD), d) 3c at diazepam binding site of HSA (PDB code, 2BXF), e) 
5c at the warfarin binding site of HSA (PDB code, 2BXD), and f) 5c at the diazepam binding site of 15 
2BXF). H-bonds (depicted by dashed lines) are shown between the titanocene ligand and each of the 
binding site residues of HSA with the bond length given in angstroms (Å). The ligand and binding site 
residues, in each case, are shown as pink and cyan sticks for the carbon atoms, respectively.  
 
Fig. 5 Docking result for 1b into fatty acid site 5 (FA5) of 1E7E showing exposure of titanocene. 20 
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Fig.3 
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Fig. 4 
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Text 
 
A molecular docking study of novel titanocene derivatives to human serum album reveals 10 
potential modes of binding to the known drug binding sites and highlights a potential new 
binding site for these derivatives. 
